MAP Pharmaceuticals Inc. (MAPP) leaped higher on Tuesday, following the announcement that its first Phase 3 clinical trial of LEVADEX met all four primary endpoints. The stock added to those gains Wednesday and closed at a 3 1/2 month high. Deutsche Securities upgraded its rating on shares of MAP Pharmaceuticals Wednesday morning from a "Hold" to a "Buy." The stock gapped up at the open and climbed throughout the middle portion of the session. MAP Pharmaceuticals closed higher by $3.15 at $12.15 on the highest volume of the year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.